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One can be stigmatized by society for having been diagnosed by genetic analysis
with a particular disease and then denied health and life insurance when the person
at that moment is perfectly capable and without a serious medical condition.
Furthermore, decisions regarding prenatal diagnosis to abort because the unborn
has been tested positive for a genetic disease discriminate against their right to live.
Prejudice, alienation and exclusion often accompany genetic associated diseases,
even though persons have no control over a disorder that is not the result of willful
behavior.
1. The Human Genome Project and Genetic Discrimination

The international effort of the human genome project, which seeks to map and
sequence all of the estimated 3 billion bp that make up the human genome, is
expected to provide information in the near future of the thousands of mutations
that are responsible for inherited diseases, thus making possible highly accurate
diagnoses. The project will provide a better understanding both of single gene
defects and multifactorial or familial diseases, such as diabetes and cancer.
While for some researchers the genome mapping project is essentially an
engineering-morally neutral-problem, many other scientists recognize the
potential ethical and sociological problems that the acquisition of the new genetic
knowledge will generate. One ethical issue for consideration is the possibility of
discrimination. The employer, insurer and state may have an interest in having
access to information from genetic tests performed on individuals with the risk of
potential genetic discrimination, such as non-equal access to work, high insurance
fees and pressure to opt for sterilization in cases of carriers of genetic diseases or
pregnancy termination in cases of embryos or fetuses with genetic mutations for
diseases.
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About 3,000 different human diseases have been shown to result from
hereditary defects on a single altered gene, and many genes may play an indirect
role in disease. l Almost 40,000 recognized disorders with a genetic component
have been recorded. 2 Some are polygenic or multifactorial, involving the
inheritance of several genes; others are monogenic, involving one gene only; others
are chromosomal, involving chromosomal aberrations; many diseases result from
the interaction of genes and the environment. Genetic diseases and congenital
malformations occur approximately in 3-5% of all live births. It is expected that
with the information generated by the human genome project, medical genetics
will permeate almost every aspect of medical research and clinical practice. The
number of genetic tests is expected to increase every year as a result of the
information gained from the project. Genetic tests detect the mutations (changes in
the genetic material) that cause the disease at the chromosomal and gene level.
Genetic Tests and Discrimination

In applying genetic tests there are complications which increase the possibility
of discrimination due to misunderstandings of the implications of test results.
Some of these are:
(I) Some genetic tests make possible the diagnosis of a disease before the
symptoms are produced (presymptomatic diagnosis). Predictive diagnosis for late
onset diseases, such as Huntington disease, is becoming increasingly possible. In
this type of disease the person can live free of its effects during most oflife. (2) Even
when the genetic defect is present, some diseases may never be fully expressed; for
example, 20 percent of persons who carry the gene for fragile-X, the most
common form of mental retardation, never express any form of mental
retardation. (3) Though genetic tests for susceptibility to certain diseases, such as
for coronary heart disease and cancer, will be developed, these can only provide
probabilistic information whether an increased risk exists. (4) Errors in the
diagnosis depending on the disease, the type of mutation, and the test employed
may also occur. Indeed, differentiation between harmless polymorphic alterations
and disease-causing mutations is difficult without the additional work of
sequencing, which is not always feasible. In the case of a test for detecting a
polymorphism in a nearby region of the mutated gene, which is inherited with the
disease, there is the chance, although slight, of genetic recombination which yields
false results. (5) For many of the diseases there is genetic heterogeneity so that
more than one mutation and/or gene are involved; particularly X-linked diseases
are prone to newly arising mutations so that almost every affected family displays a
different alteration. Testing for the large number of mutations that may be
involved is usually not feasible and it can lead to misdiagnosis if the particular
mutation causing the disease is not covered by the test. (6) Even with the same
mutations in some cases (susceptibility-conferring mutation) there are markedly
variable clinical expressions depending on environmental factors and modifying
genes that interact with the mutated gene. (7) Even when a particular disease can
be diagnosed, in many cases there is no cure for it. (8) The process of explaining
genetic risks is complex and easily misunderstood by people without a background
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in genetics. Genetic counselors and doctors and nurses with adequate background
in genetics are necessary. (9) It will take time until a consensus is reached by the
medical community about which genetic tests have sufficient predictive value for
specific diseases. 3
With the new information generated by the genome project the probability of
finding mutant genes is going to be greatly magnified, so that the possibilities of
being stigmatized will be much greater.
3. Genetic Discrimination and Health Insurance

One potential risk of genetic discrimination, based on the acquisition of
information through genetic tests, is in relation to the insurance industry. Insurance
companies can discriminate by denying life, health or disability insurance to
people on the basis of their genotypes. The current health-care system in the
United States focuses on treatment rather than on prevention. For that reason, the
predictive value of genetic tests is of little positive value for insurance companies.
But, health insurance companies, in order to keep their prices down and to be
competitive with other companies, may refuse to insure people who are at risk of
having high medical expenses. As a result, some people cannot afford insurance
because they are already ill or are at risk of illness. Through the principles of
underwriting, insurers estimate the chances that an applicant will make a claim.
The notion of "actuarial fairness" plays a key role in this estimation. By means of it,
parties seeking insurance ought to pay according to their potential risks for filing a
claim. Many insurance companies require physical examinations which
sometimes reveal genetic disorders, and ask questions of the applicants which may
elicit information about their genetic background. Applicants are also asked to
permit release of medical information from doctors who previously have treated
them. There are no safeguards to prevent insurance companies from exchanging
stigmatizing information with employers during the claim process. During
underwriting, physicians commonly release genetic information to insurers. 4
At present it appears that insurance companies do not require molecular genetic
tests in underwriting or in the process of establishing premiums according to the
risk of developing diseases. Still, insurers make decisions based on genetic
information, including family history or prior diagnostic tests performed on the
client or his/her family. Many companies require policyholders to sign releases
that allow access to any and all records. Currently most genetic information
available is too costly to be used as a routine insurance screen. However, with
technological advances it is expected that genetic testing will be included in
insurance underwriting in the near future by using cost-effective multiple tests. The
common, severe and costly diseases are most likely to attract insurers' interest once
the predictive value of a genetic test is confirmed and the word spreads among
insurers. Biotechnology firms are interested in developing diagnostic tests for
genetic disorders and one potential market for the use of these tests is the insurance
industry.5 Insurers insist that they must not be prevented from using data on
genetic-testing already collected in the medical record to assess risk of candidates
for initial coverage in order to protect the companies and other policyholders from
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the results of adverse selection.6
Adverse selection consists in the tendency of people who learn they have higher
risks of disease to purchase insurance. This occurs when individuals have more
information about their risk of illness than do insurance companies. Adverse
selection poses a greater problem to insurance companies for life and disability
insurance since these forms of insurance are obtained through individual
applications. Insurance companies claim that adverse selection will jeopardize
their interests and for that reason they are developing strategies to protect
themselves. Because of competition among insurance companies, the tendency
will be towards screening for predisposition. If one insurance company begins to
use genetic tests and is able to offer lower rates to individuals who are not
predisposed to disease and higher rates to individuals who have predisposition to
disease, this particular insurance company would draw people who are offered
low rates and this will put pressure on other insurance companies to also offer
genetic tests. In this way insurers can assess the risk of candidates for initial
coverage, their renewal or increased coverage or decide not to cover certain
indi viduals.7
On the other hand, the health insurance industry has been criticized for
practicing "adverse selection," for example, by discontinuing coverage when a
client, who has been faithfully paying premiums, is found to have a serious
condition.s The proliferation of new genetic tests heightens the concern that
insurance companies, requiring applicants to provide blood samples, may perform
genetic tests on them without making the results known to the clients.9 In the
absence of a cure for most genetic diseases, insurers will be reluctant to insure
people at risk of developing costly disorders. This issue provides a high potential
for discriminatory practices.

4. Genetic Discrimination and Abortion

Genetic discrimination may result in the abortion of an individual who tests
positive for a genetic disease by prenatal diagnosis, although every human being
-including fetuses - has the right to receive adequate medical attention if needed.
The possibility that insurance companies will refuse in the future to insure
individuals who, as fetuses are shown to have a genetically inherited disease, will
put pressure on families to abort because of economical constraints. Furthermore,
if abortion of genetically defective embryos or fetuses becomes widespread, there
is the danger of reinforcing negative attitudes in society against people born with
disabilities. Theoretically, for single gene disorders for which there is no present
cure, to try to develop gene therapy constitutes an alternative.ln reality, however,
the impetus for developing this therapy is blunted by the use of gene probes and
other diagnostic technologies to detect and abort affected fetuses and to counsel
at-risk adults against procreation. Furthermore, the practice of embryo selection in
in vitro fertilization procedures is as well discriminatory, since the embryos not
selected are very rarely given the chance to develop.
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5. Ethical Reflection

I consider that ethical reflection needs a proper definition of personhood on
which to base moral decisions. For example, moral decisions with respect to the
implementation of genetic knowledge depend on the value given to the person as a
whole. In a society where there is confusion over what it means to be a person,
there is also a confusion over what is moral. It is then necessary to consider the
definition of personhood in accordance with the dignity due to a human being.
Genesis (1 :26) gives a transcendental meaning of what a human being is, revealing
that he/she is "image and likeness" of the Divine being. Through the motif of the
image of God (cf. Ps 8:5; Wis 2:23; 1Cor 11 :7) the Bible affirms the sacredness and
dignity of every human person. According to Gula this statement contains the
theological meaning that God has established a relationship with human persons
which is sustained by divine faithfulness and 10ve.1O The statement also contains
the anthropological meaning that we all share a common human condition with
God as common end, and that human dignity does not depend on human
achievements alone, but on divine love as well. For the contemporary philosopher
Fernando Rielo this statement implies that the Divine being is forming
ontologically the human being. II Personhood cannot be defined by something
inferior to itself. To assert this would be to reduce the person to a property, such as
intellectual capacity, independence, etc. Rather, personhood should be defined by
a term, the Absolute being, that transcends and encompasses all these
characteristics. The essence of the human person is to be a being in relation to God,
thereby to other human beings and to the whole of nature. This definition renders
morally prohibitive any action that would in any way compromise the proper
realization of this relationship. Faith helps Christians to see the dignity of a human
being against cultural pressures that distort it. The capacity of the human being to
establish human rights and the ethical obligation to carry them out confirms that
the person cannot be reduced to a naive or moderate materialism.
The Magisterium has consistently taught the dignity of human beings and the
inviolability of human life. Human dignity, rooted in the Bible, arises from three
sources: creation in the image of God (Gen. 1:26), redemption, achieved through
the incarnation, death and resurrection of Jesus Christ (In 3:16; Eph 1:10; 1 Tim
2:4-6), and our common destiny to share a life with God beyond all corruption (I
Cor 15:42-57; I Jn 3:1-2).12 When the Magisterium asserts that human life is
sacred, given that from the beginnings it involves "the creative action of God and it
remains forever in a special relationship with the Creator, who is its sole end,"J3
and that "the spiritual soul of each man is immediately created by God",14 it is
arguing that there is no separation between the spiritual dimension of the person
and the individual's physical life, since both are present from the beginning.
Human life therefore is sacred; it has been touched by God and deserves the highest
respect from the moment of conception.
Morally every individual should be given the highest value regardless of race,
ethnicity, social condition, age, sex, stage of embryonic or fetal development,
religion or physical health. All human beings deserve respect and protection and
34

Linacre Quarterly

promotion of their basic rights because of their dignity. The value of a person
cannot be measured by his/her genetic constitution. Knowledge of the genetic
cause of diseases has as its final objective the cure or prevention of the disease, not
the elimination or discrimination of the individuals that possess genetic mutations.
Virtually all human beings possess one or another genetic mutation. The fact that
one has mutations does not necessarily mean that this is an evil. Part of the function
of mutations is an evolutionary strategy to provide a reservoir for adapting to
changing environmental circumstances. Performing genetic testing for the purpose
of eliminating the individuals that do not test normal is clearly immoral. Choosing
embryos with a particular genotype in in vitro fertilization procedures is immoral
because it implies making a judgment regarding which embryo deserves to be
developed and which one does not; ultimately this is a value judgment concerning
who has the right to live and who does not. The embryos which are not destined to
grow must be frozen, destroyed or used for research, which clearly violates human
dignity.
Performing genetic tests with the purpose of identifying individuals who do not
test normal and then denying them insurance or other basic values is immoral
because it violates the right to receive health benefits. This goes against justice. I
consider that the practice of establishing premiums based on risk by insurers is
unj ust and therefore a better system must be found. The notion of actuarial fairness
does not coincide with moral fairness. The expenses of health care should be
shared by all equally with the establishment of adequate social policies. It is not
right that because somebody has been born with a genetic disease, he/she has to
pay more. This puts pressure on families to avoid having a defective child and
leaves society with the impression that it is better not to care for those who have
abnormalities. We are here in life to help others, not to put further difficulties on
those who have been born with health problems. The present health care system in
the US does not promote equal opportunity since access to health care depends, for
the most part, on the ability to pay. The health care system should reject the
possibility that individuals can have economic advantage from differences in their
health risk. On the other hand, enhancement services, such as "cosmetic surgery,"
could be excluded from coverage on the ground that it does not constitute a
treatment of disease and there is no social obligation for it.

Conclusion
Maximum respect for human dignity should be the guiding principle in all
ethical decisions. If the person is an "image" of God, then maximum respect and
treatment should be given to the person, without discrimination, regardless of race,
ethnicity, genetic constitution or stage of development. Laws that permit abortion
or active euthanasia go against human dignity. Health is not an absolute end, but a
subordinate goal; thus it is not the case that if you are not going to be healthy, it is
better that you do not live; rather, health is a means for improving the quality oflife
for which we strive. It is necessary to emphasize the value and the importance of
every human being.
A reform in the health care system in this country could prevent the possibility
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of genetic discrimination by insurance companies by assuring access to care for
everyone. At present the law does not seem to prevent insurers from exercising
genetic discrimination. The general applicability of genetic tests may force the
situation in the direction of socialized medicine, which will be more effective in
handling the problem. This is critical for cases of (1) presymptomatic diagnosis in
which the patient is at risk of having high insurance premiums in the present
system instead of receiving preventive care, and (2) for prenatal diagnosis of
diseases for which there is no cure.
Abortion for fetal indications is immoral because it involves the end of a life,
when life constitutes a higher value than the suffering a human being will have to
undergo if genetically injured. Society has the duty to try to provide the best
environment possible to diminish the suffering of individuals born with diseases. If
there are no institutions that care and help individuals with genetic diseases, all the
burden falls on family members who are pressured to avoid the birth of these
individuals. Hence the development of needed services and institutions is clearly a
societal responsibility.
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